Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
P/S ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | (382.85) | — | — | — | — | — | — | — | — |
P/FCF ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
P/Operating CF |
— | (8.85) | — | — | — | — | — | — | — | — |
P/B ratio |
— | 0.00 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
— | 0.00 | — | — | — | — | — | — | — | — |
EV/Sales |
— | 0.00 | — | — | — | — | — | — | — | — |
EV/EBITDA |
— | 0.00 | — | — | — | — | — | — | — | — |
EV/Operating CF |
— | (5.55) | — | — | — | — | — | — | — | — |
EV/FCF |
— | (5.81) | — | — | — | — | — | — | — | — |
Quick Ratio |
0.28 | 0.10 | 0.06 | 0.84 | 4.28 | 2.51 | 4.77 | 6.23 | 7.06 | 0.01 |
Current Ratio |
0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 0.10 |
Net Debt/EBITDA |
0.61 | (3.49) | (0.15) | 0.21 | 0.47 | 0.41 | 0.83 | 1.03 | 1.23 | 0.01 |
Debt/Assets |
18.98% | 218.95% | 223.77% | 59.35% | 26.58% | 43.87% | 25.17% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.08) | (0.27) | (0.17) | (1.18) | 0.54 | 1.14 | 0.41 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 2.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.06 | 1.50 | 0.84 | 0.88 | 0.52 | 0.81 | 0.77 | 0.66 | 0.67 | 0.31 |
Capex/Depreciation |
0.00 | 0.06 | 0.29 | (0.05) | (0.06) | 0.00 | (0.05) | (1.06) | (0.34) | 1.08 |
Interest Coverage |
— | — | — | — | — | — | — | — | — | (17.32) |
| 33.08% | 13.39% | 102.55% | (615.23%) | (409.19%) | (148.90%) | (128.59%) | (146.83%) | (212.48%) | (228.24%) | |
| (145.40%) | (134.09%) | (149.37%) | (108.86%) | (186.35%) | (80.95%) | (92.78%) | (124.99%) | (154.22%) | (211.94%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (342.55%) |
Return on Tangible Assets |
50.35% | 12.92% | 80.77% | 1,291.26% | (197.76%) | (213.60%) | (110.35%) | (110.29%) | (110.57%) | 254.01% |
Average Days of Receivables |
— | 156.01 | — | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 56.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 82.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 8.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.16) | — | — | — | — | — | — | — | — |
Graham Number |
— | 0.00 | — | — | — | — | — | — | — | — |
Earnings Yield |
— | (151.20%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
— | (15.86%) | — | — | — | — | — | — | — | — |
Revenue per Share |
0.00 | 18.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(5.64) | (13.80) | (61.36) | (161.73) | (220.13) | (308.84) | (455.39) | (425.60) | (1,410.18) | (36.46) |
Capex per Share |
0.00 | 0.11 | 1.32 | (0.34) | (0.56) | 0.00 | (0.44) | (3.11) | (20.97) | 0.90 |
Free Cash Flow per Share |
(5.64) | (13.69) | (60.04) | (162.07) | (220.69) | (308.84) | (455.83) | (428.71) | (1,431.15) | (35.56) |
Cash per Share |
4.27 | 0.34 | 5.79 | 98.87 | 267.72 | 271.10 | 651.09 | 660.12 | 2,137.26 | 0.63 |
Shareholders Equity per Share |
(10.61) | (71.22) | (96.70) | (54.14) | 140.78 | 112.17 | 418.65 | 582.24 | 1,890.35 | 16.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(10.61) | (71.22) | (96.70) | (54.14) | 140.78 | 112.17 | 418.65 | 582.24 | 1,890.35 | 16.50 |
Free Cash Flow |
(6.33) | (4.68) | (14.03) | (31.91) | (35.09) | (28.17) | (39.43) | (31.60) | (16.17) | (1.88) |
Working Capital |
(11.91) | (24.33) | (21.15) | (2.96) | 33.53 | 16.06 | 45.90 | 42.53 | 21.08 | (2.49) |
Capital Expenditures |
0.00 | 0.04 | 0.31 | (0.07) | (0.09) | — | (0.04) | (0.23) | (0.24) | 0.05 |
Net Current Asset Value |
(11.91) | (24.33) | (22.76) | (11.65) | 20.73 | 9.65 | 34.98 | 42.53 | 21.08 | (4.69) |
EV/EBIT |
— | 0.00 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | (0.01) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 30.51 | 7.31 | 6.39 | 8.64 | 3.95 | 0.87 | 2.54 | 0.86 |
Cash ROIC |
103.43% | 26.42% | 80.58% | (149.50%) | (45.60%) | (60.48%) | (36.72%) | (34.51%) | (35.53%) | (207.61%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
4.03 | 5.52 | 4.36 | 2.20 | 0.93 | 1.18 | 1.31 | 1.14 | 0.86 | 0.14 |
Average Assets |
4.12 | 2.34 | 11.42 | 33.13 | 35.81 | 42.71 | 54.83 | 37.75 | 15.31 | 2.92 |
Average Common Equity |
(18.12) | (23.47) | (16.63) | 5.86 | 16.31 | 23.22 | 39.56 | 32.14 | 11.12 | 2.71 |
Columns are period end dates